Protagenic Therapeutics, Inc.\new

Distress signal

Moderate confidence (50%)

Updated Oct 16, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: Protagenic Therapeutics, Inc.\new was delisted from its exchange (Jan 23, 2026)

Every material event, newest first. History is never overwritten.

Protagenic Therapeutics, Inc.\new was delisted from its exchange
Jan 23, 2026
Delisting effective
- SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001022899 Protagenic Therapeutics, Inc.\new 001-12555 149 Fifth Ave Suite 500 New York NY NEW YORK 10010 213-260-4342 Common Stock, Warrants 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-01-23”
Protagenic Therapeutics, Inc.\new received a delisting notice from its exchange
Dec 31, 2025
Delisting notice received
- SEC EDGAR — “Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. OTC Trading and Next Steps Beginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company ) expects its common stock ( PTIX ) and warrants ( PTIXW ) to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC ( Nasdaq ) stating that trading of the Company s securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company s securities ba…”

Every material source used to build this profile.

SEC Company Submissions (TIER 1 · UNVERIFIED)
Protagenic Therapeutics, Inc.\new — Pharmaceutical Preparations (SIC 2834) — NEW YORK, NY
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
X0203 0001354457 Nasdaq Stock Market LLC 0001022899 Protagenic Therapeutics, Inc.\new 001-12555 149 Fifth Ave Suite 500 New York NY NEW YORK 10010 213-260-4342 Common Stock, Warrants 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-01-23
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. OTC Trading and Next Steps Beginning January 5, 2026, Protagenic Therapeutics, Inc. (the Company ) expects its common stock ( PTIX ) and warrants ( PTIXW ) to be quoted for trading on the over-the-counter market. On December 31, 2025, the Company received a letter from The Nasdaq Stock Market LLC ( Nasdaq ) stating that trading of the Company s securities on Nasdaq would cease at the close of trading on January 2, 2026, and that Nasdaq determined to delist the Company s securities ba…
View source record

Every derived status, with the rule that produced it.

DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:30 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:11 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:34 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:47 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:59 AM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:54 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.